Primary radiation therapy for localized prostate cancer

Tony Y. Eng, Charles R. Thomas, Terrence S. Herman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Prostate cancer in men is similar to breast cancer in women; both cancers rank first, respectively, in incidence and are normally responsive to radiation therapy. In addition, advances in mammography help detect earlier breast cancers, and the development and refinement of prostatic specific antigen (PSA) has resulted in early detection of low-stage localized prostate cancers. This has generated debate over the proper management of localized prostate cancer. While there have not been any controlled, prospective, randomized trials of sufficient power to compare the various local therapies, based on the current available data, the three commonly used local modalities, surgery, and external beam radiation therapy and brachytherapy (radioactive seed implant), have similar efficacy controlling the disease up to 10 years in many patients. Technological advances in treatment delivery and planning have improved the treatment of prostate cancer with external-beam radiotherapy using three-dimensional conformal radiotherapy (3DCRT), ultrasound-guided transperineal implant, or intensity-modulated radiotherapy (IMRT), as well as proton or neutron beam based therapies.

Original languageEnglish (US)
Pages (from-to)239-257
Number of pages19
JournalUrologic Oncology
Volume7
Issue number6
DOIs
StatePublished - Nov 2002

Fingerprint

Prostatic Neoplasms
Radiotherapy
Breast Neoplasms
Conformal Radiotherapy
Intensity-Modulated Radiotherapy
Brachytherapy
Neutrons
Mammography
Therapeutics
Protons
Seeds
Randomized Controlled Trials
Antigens
Incidence
Neoplasms

Keywords

  • Brachytherapy
  • External beam radiation therapy
  • Intensity-modulated radiotherapy
  • Prostate cancer
  • PSA
  • Three-dimensional conformal radiotherapy
  • Ultrasound-guided transperineal implant

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Primary radiation therapy for localized prostate cancer. / Eng, Tony Y.; Thomas, Charles R.; Herman, Terrence S.

In: Urologic Oncology, Vol. 7, No. 6, 11.2002, p. 239-257.

Research output: Contribution to journalArticle

Eng, Tony Y. ; Thomas, Charles R. ; Herman, Terrence S. / Primary radiation therapy for localized prostate cancer. In: Urologic Oncology. 2002 ; Vol. 7, No. 6. pp. 239-257.
@article{d197e84621ff442bbd124046b52731b4,
title = "Primary radiation therapy for localized prostate cancer",
abstract = "Prostate cancer in men is similar to breast cancer in women; both cancers rank first, respectively, in incidence and are normally responsive to radiation therapy. In addition, advances in mammography help detect earlier breast cancers, and the development and refinement of prostatic specific antigen (PSA) has resulted in early detection of low-stage localized prostate cancers. This has generated debate over the proper management of localized prostate cancer. While there have not been any controlled, prospective, randomized trials of sufficient power to compare the various local therapies, based on the current available data, the three commonly used local modalities, surgery, and external beam radiation therapy and brachytherapy (radioactive seed implant), have similar efficacy controlling the disease up to 10 years in many patients. Technological advances in treatment delivery and planning have improved the treatment of prostate cancer with external-beam radiotherapy using three-dimensional conformal radiotherapy (3DCRT), ultrasound-guided transperineal implant, or intensity-modulated radiotherapy (IMRT), as well as proton or neutron beam based therapies.",
keywords = "Brachytherapy, External beam radiation therapy, Intensity-modulated radiotherapy, Prostate cancer, PSA, Three-dimensional conformal radiotherapy, Ultrasound-guided transperineal implant",
author = "Eng, {Tony Y.} and Thomas, {Charles R.} and Herman, {Terrence S.}",
year = "2002",
month = "11",
doi = "10.1016/S1078-1439(02)00198-9",
language = "English (US)",
volume = "7",
pages = "239--257",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Primary radiation therapy for localized prostate cancer

AU - Eng, Tony Y.

AU - Thomas, Charles R.

AU - Herman, Terrence S.

PY - 2002/11

Y1 - 2002/11

N2 - Prostate cancer in men is similar to breast cancer in women; both cancers rank first, respectively, in incidence and are normally responsive to radiation therapy. In addition, advances in mammography help detect earlier breast cancers, and the development and refinement of prostatic specific antigen (PSA) has resulted in early detection of low-stage localized prostate cancers. This has generated debate over the proper management of localized prostate cancer. While there have not been any controlled, prospective, randomized trials of sufficient power to compare the various local therapies, based on the current available data, the three commonly used local modalities, surgery, and external beam radiation therapy and brachytherapy (radioactive seed implant), have similar efficacy controlling the disease up to 10 years in many patients. Technological advances in treatment delivery and planning have improved the treatment of prostate cancer with external-beam radiotherapy using three-dimensional conformal radiotherapy (3DCRT), ultrasound-guided transperineal implant, or intensity-modulated radiotherapy (IMRT), as well as proton or neutron beam based therapies.

AB - Prostate cancer in men is similar to breast cancer in women; both cancers rank first, respectively, in incidence and are normally responsive to radiation therapy. In addition, advances in mammography help detect earlier breast cancers, and the development and refinement of prostatic specific antigen (PSA) has resulted in early detection of low-stage localized prostate cancers. This has generated debate over the proper management of localized prostate cancer. While there have not been any controlled, prospective, randomized trials of sufficient power to compare the various local therapies, based on the current available data, the three commonly used local modalities, surgery, and external beam radiation therapy and brachytherapy (radioactive seed implant), have similar efficacy controlling the disease up to 10 years in many patients. Technological advances in treatment delivery and planning have improved the treatment of prostate cancer with external-beam radiotherapy using three-dimensional conformal radiotherapy (3DCRT), ultrasound-guided transperineal implant, or intensity-modulated radiotherapy (IMRT), as well as proton or neutron beam based therapies.

KW - Brachytherapy

KW - External beam radiation therapy

KW - Intensity-modulated radiotherapy

KW - Prostate cancer

KW - PSA

KW - Three-dimensional conformal radiotherapy

KW - Ultrasound-guided transperineal implant

UR - http://www.scopus.com/inward/record.url?scp=0036868271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036868271&partnerID=8YFLogxK

U2 - 10.1016/S1078-1439(02)00198-9

DO - 10.1016/S1078-1439(02)00198-9

M3 - Article

C2 - 12504845

AN - SCOPUS:0036868271

VL - 7

SP - 239

EP - 257

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 6

ER -